News Related to Molluscum Contagiosum

Related coverage linked through entity extraction aliases.

Aurobindo Pharma Subsidiaries Secure FDA, Health Canada, and EU Biosimilar Approvals and Partnerships

May 01, 2026

Aurobindo Pharma's subsidiaries secured Health Canada approval for bevacizumab biosimilar Bevqolva, an EU distribution deal with STADA for two EMA-approved biosimilars, and US FDA approval for ADQUEY ointment for atopic dermatitis.

Alphyn Biologics Doses First Patients in Phase 2 Trial for Molluscum Contagiosum Treatment

Feb 18, 2026

Alphyn Biologics has dosed the first patients in a Phase 2 trial of Zabalafin Hydrogel for Molluscum Contagiosum, enrolling 54 patients ages 6 months and older in a placebo-controlled study targeting 75% lesion elimination.